The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

The meeting, scheduled for June 25-26, will review existing data and vote on RSV and influenza vaccines, along with ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed ...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes. To be known as Viela Bio, the spin-out ...

MedImmune will explore the target, linker, warhead selection: Do's and Don’ts; five rights of creation of the best optimized fit-for-purpose ADCs; internalisation of ADCs – how to improve ...

Objective IBD therapies and treatments are evolving to deeper levels of remission. Molecular measures of disease may augment current endpoints including the potential for less invasive assessments.

MedImmune Inc. Profit and Loss IND: Others | ISIN code: | SECT: General The P&L A/C page of MedImmune Inc. presents the key P&L A/c Ratios, its comparison with the sector peers and 5 years of Profit & ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

Pre-MedImmune v Genentech, a patentee would send my client a cease-and-desist. In turn, I would assemble prior art and a claim chart, showing why the patented claims are invalid, not infringed, or ...

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...